Form 4: Korro Bio Director Katharine Knobil Receives Stock Options

Director Katharine Knobil was granted 14,677 stock options in Korro Bio, Inc. as part of standard equity compensation.

Summary

• Director Katharine Knobil received a grant of 14,677 stock options to purchase common stock in Korro Bio, Inc.
• The options have an exercise price of $10.59 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $10.59 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board member retention and alignment with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation practices for mid-cap and small-cap biotech firms.
• Vesting schedules tied to annual meetings are common industry practice for non-employee directors.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Insider Trading, Stock Options, Director Compensation